圣达生物(603079) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥224,395,495.23, representing a year-on-year increase of 23.92%[2] - The net profit attributable to shareholders for Q3 2024 was ¥5,184,192.38, a significant increase of 95.99% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses reached ¥4,462,407.04, reflecting a remarkable growth of 557.91% year-on-year[2] - The basic earnings per share for Q3 2024 was ¥0.03, an increase of 50.00% compared to the same period last year[4] - The diluted earnings per share for Q3 2024 was also ¥0.03, marking a 50.00% increase year-on-year[4] - Total operating revenue for the first three quarters of 2024 reached CNY 608,870,278.32, an increase of 11.9% compared to CNY 544,108,238.57 in the same period of 2023[20] - Net profit for the first three quarters of 2024 was CNY 27,409,202.51, a significant recovery from a net loss of CNY 2,626,697.31 in the same period of 2023[20] - The company reported a basic and diluted earnings per share of CNY 0.13 for the first three quarters of 2024, compared to a loss of CNY 0.02 in the same period of 2023[22] Cash Flow - The cash flow from operating activities for the year-to-date period was ¥81,273,978.16, showing a substantial increase of 429.00% compared to the previous year[2] - The net cash flow from operating activities increased to ¥81,273,978.16, compared to ¥15,363,815.47 in the previous year, reflecting a significant improvement[23] - Cash inflow from operating activities totaled ¥630,322,252.29, up from ¥591,147,959.53 year-over-year[23] - Cash outflow from operating activities decreased to ¥549,048,274.13 from ¥575,784,144.06, indicating better cost management[23] - The net cash flow from investing activities was -¥215,604,257.27, worsening from -¥149,919,673.60 in the previous year, primarily due to increased investment expenditures[24] - Cash inflow from investing activities rose to ¥108,199,568.08, compared to ¥23,575,218.34 in the previous year, driven by higher cash recovered from investments[24] - Cash outflow from investing activities increased to ¥323,803,825.35 from ¥173,494,891.94, reflecting a strategic push in capital expenditures[24] - The net cash flow from financing activities was -¥28,408,400.53, a decline from ¥129,183,362.70 in the previous year, indicating reduced financing activities[24] - Cash inflow from financing activities decreased to ¥132,000,000.00 from ¥178,000,000.00, showing a reduction in borrowing[24] - The ending cash and cash equivalents balance was ¥145,548,823.61, down from ¥300,424,462.60, highlighting liquidity challenges[24] - The company reported a significant increase in cash received from investment recoveries, amounting to ¥105,000,000.00, compared to ¥22,000,000.00 in the previous year[23] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,739,660,936.95, reflecting a slight increase of 1.19% from the end of the previous year[4] - As of September 30, 2024, total current assets amounted to RMB 666,883,511.03, a decrease from RMB 695,148,552.16 as of December 31, 2023[16] - The company's total assets reached RMB 1,739,660,936.95, compared to RMB 1,719,185,557.88 at the end of 2023, indicating a slight increase[17] - Long-term borrowings increased to RMB 210,000,000.00 from RMB 144,000,000.00, reflecting a significant rise in non-current liabilities[17] - The company’s total liabilities decreased to RMB 239,899,213.71 from RMB 295,454,343.18, indicating improved financial leverage[17] - The total liabilities increased to CNY 465,535,062.96 from CNY 449,195,537.01, marking a rise of 3.0%[20] - The total equity attributable to shareholders of the parent company was CNY 1,253,086,190.35, a slight decrease from CNY 1,254,680,511.87[20] Shareholder Information - The company reported a total of 18,323 common shareholders at the end of the reporting period[9] - Zhejiang Shengda Group Co., Ltd. held 26.51% of the shares, with 10,400,000 shares pledged[9] - The top 10 shareholders include Zhejiang Shengda Group Co., Ltd. with 45,375,792 shares and Tian Tai Wan Jian Investment Development Center with 32,771,141 shares[11] - The company has not reported any changes in the participation of its top shareholders in margin financing and securities lending activities[12] - The actual controller of the company is Hong Ai, who is also the spouse of Zhu Yonggang, a significant shareholder[11] - The company has not disclosed any related party transactions or agreements among its shareholders beyond those mentioned[11] Investment and Fundraising - The company plans to issue up to 51,356,687 A-shares to specific investors, aiming to raise a total of no more than 500 million RMB for production projects[13] - The adjusted total amount for the fundraising has been revised from 500 million RMB to 267.61 million RMB[13] - The company is investing in the production of 3 billion soft capsules and 3 billion solid preparations, along with a project for an annual output of 20,000 tons of D-isoascorbic acid and its sodium salt[13] - The company received an inquiry letter from the Shanghai Stock Exchange regarding its stock issuance application, with responses provided on multiple occasions[13] - The company has not engaged in any share buyback activities during the reporting period[13] - The company completed a share repurchase plan, acquiring 1,872,500 shares, representing 1.09% of total equity, at an average price of RMB 11.79 per share, totaling RMB 22,078,434.00[14] - The company plans to implement an employee stock ownership plan, with a maximum of 872,500 shares to be held, funded by a total of RMB 499.95 million[14] Research and Development - Research and development expenses amounted to CNY 29,025,818.97, slightly down from CNY 30,185,572.78 in the previous year[20] Tax and Investment Income - The company recorded an investment income of CNY 3,015,295.08, compared to CNY 735,390.44 in the previous year, indicating a positive trend[20] - Deferred income tax liabilities decreased to CNY 3,047,545.31 from CNY 4,276,770.45, showing a reduction of 28.7%[20]